Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Eoganacht


V.TLT

RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

Yes that makes sense. It seems that 29% of patients didn't respond, 55...

April 20, 2023

V.TLT

Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

It turns out that this treatment achieved a 2 year CR rate of 35%. I believe...

April 20, 2023

V.TLT

Shout Out to TLD1433 PDT by Spanish Researchers

Spanish researchers cite the pioneering phase 2 trial of TLD1433 PDT as the...

April 19, 2023

V.TLT

RE:RE:RE:RE:I don't see a mystery

Plus this is a combo treatment which is dependent on BCG which is in short...

April 18, 2023

V.TLT

RE:RE:RE:RE:Accelerated Approval

It's not apples to apples. Although TLD1433 outdid Adstiladrin's CE...

April 17, 2023

V.TLT

RE:RE:Accelerated Approval

51% achieved a CR at any time. 46% of that 51% were still CR at one year. 46%...

April 17, 2023

V.TLT

Repost of CancerSlayer's Response on Jan 15

(In the repost I accidentally typed Cohort B when I meant Cohort C) Hi...

April 17, 2023

V.TLT

Repost from Jan 15 about Immunitybio Efficacy

FDA to rule on BLA for N-803 + BCG for NMIBC by May 23, 2023 If...

April 17, 2023

V.TLT

Accelerated Approval

According to a page on their website the FDA does not set the bar very high...

April 17, 2023

V.TLT

RE:RE:Let the 450 day CR% numbers talk.

That Table didn't come across very well:        ...

April 16, 2023

V.TLT

RE:Let the 450 day CR% numbers talk.

Great post wildbird1 ! Our efficacy results already beat both of the FDA...

April 16, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:AUA Poster Session

We'll likely get an MD&A with trial update on Thursday Apr 27 or...

April 12, 2023

V.TLT

RE:RE:RE:AUA Poster Session

These are the same results provided in the initial ASCO presentation...

April 11, 2023

V.TLT

AUA Poster Session

I assume the data will be updated like it was for the ASCO presentation...

April 11, 2023

V.TLT

RE:AUA Conference April 28-May 1st, 2023, GOOD NEWS a commin!

Thanks for that Jaro. It's great to see Theralase has it's own booth.

April 11, 2023

V.TLT

RE:RE:RE:RE:News please...

Agreed! For all the reasons cited by ScienceFirst and CancerSlayer, (IMHO...

April 11, 2023

V.TLT

RE:RE:News please...

Right. Theralase shareholder - potential Moneybags or Bagholder. Only time...

April 11, 2023

V.TLT

RE:RE:RE:Range of CR at 450 day mark

10% more CRs means 10 more patients out of every 100 who get to keep their...

April 5, 2023

V.TLT

RE:Range of CR at 450 day mark

It's unlikely that the 2 CRs from 360 days will become IR or NR at 450...

April 5, 2023

V.TLT

RE:RE:Patent Action Today

In 2017 they were talking about Osmium-based compounds TLD1822, TLD1824 and...

April 4, 2023

Featured Company